Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, discusses COVID-19 vaccinations among people with diabetes as they have been disproportionally affected by the pandemic.
Efforts to address COVID-19 in the diabetes community are based, in part, on early recognition that these individuals would be disproportionately impacted, said Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association.
Transcript
Is the focus on how much COVID-19 has harmed those with diabetes making an impact? Are people with diabetes getting vaccinated at rates that will make a difference?
There's been a big effort to address COVID-19 in the diabetes community. That, in part, is based on some early recognition that people with diabetes have disproportionately suffered as a result of the pandemic. Whether that's a statistic, like up to 40% of the deaths associated with COVID-19 are people with diabetes, or that people with diabetes are 6 times more likely to be hospitalized, or 12 times more likely to die from COVID-19. So the American Diabetes Association has developed a series of resources for both providers but also, importantly, for people living with diabetes, where they can find out about vaccination, where they can get the latest information, what to do if they get sick, and what are the precautions they can take. The good news is that vaccination rates are rising; we're hoping to have that rise even more. And now we're focused on boosters, because people with diabetes are amongst that high risk group again, that needs to get a booster and so we're encouraging people to do that.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen